GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.

IF 3.5 4区医学 Q3 CELL BIOLOGY

Pathobiology Pub Date : 2023-01-01 Epub Date: 2023-01-17 DOI:10.1159/000527382

Viktor Reiswich, Carol E Schmidt, Maximilian Lennartz, Doris Höflmayer, Claudia Hube-Magg, Sören Weidemann, Christoph Fraune, Franziska Büscheck, Katharina Möller, Christian Bernreuther, Ronald Simon, Till S Clauditz, Niclas C Blessin, Elena Bady, Guido Sauter, Ria Uhlig, Stefan Steurer, Sarah Minner, Eike Burandt, David Dum, Andreas H Marx, Till Krech, Patrick Lebok, Andrea Hinsch, Frank Jacobsen

{"title":"GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.","authors":"Viktor Reiswich, Carol E Schmidt, Maximilian Lennartz, Doris Höflmayer, Claudia Hube-Magg, Sören Weidemann, Christoph Fraune, Franziska Büscheck, Katharina Möller, Christian Bernreuther, Ronald Simon, Till S Clauditz, Niclas C Blessin, Elena Bady, Guido Sauter, Ria Uhlig, Stefan Steurer, Sarah Minner, Eike Burandt, David Dum, Andreas H Marx, Till Krech, Patrick Lebok, Andrea Hinsch, Frank Jacobsen","doi":"10.1159/000527382","DOIUrl":null,"url":null,"abstract":"Introduction: GATA3 is a transcription factor involved in epithelial cell differentiation. GATA3 immunostaining is used as a diagnostic marker for breast and urothelial cancer but can also occur in other neoplasms.Methods: To evaluate GATA3 in normal and tumor tissues, a tissue microarray containing 16,557 samples from 131 different tumor types and subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry.Results: GATA3 positivity was found in 69 different tumor types including 23 types (18%) with at least one strongly positive tumor. Highest positivity rates occurred in noninvasive papillary urothelial carcinoma (92-99%), lobular carcinoma (98%), carcinoma of no special type of the breast (92%), basal cell carcinoma of the skin (97%), invasive urothelial carcinoma (73%), T-cell lymphoma (23%), adenocarcinoma of the salivary gland (16%), squamous cell carcinoma of the skin (16%), and colorectal neuroendocrine carcinoma (12%). In breast cancer, low GATA3 staining was linked to high pT stage (p = 0.03), high BRE grade (p < 0.0001), HER2 overexpression (p = 0.0085), estrogen and progesterone receptor negativity (p < 0.0001 each), and reduced survival (p = 0.03).Conclusion: Our data demonstrate that GATA3 positivity can occur in various tumor entities. Low levels of GATA3 reflect cancer progression and poor patient prognosis in breast cancer.","PeriodicalId":19805,"journal":{"name":"Pathobiology","volume":"90 4","pages":"219-232"},"PeriodicalIF":3.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10937041/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathobiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000527382","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: GATA3 is a transcription factor involved in epithelial cell differentiation. GATA3 immunostaining is used as a diagnostic marker for breast and urothelial cancer but can also occur in other neoplasms.

Methods: To evaluate GATA3 in normal and tumor tissues, a tissue microarray containing 16,557 samples from 131 different tumor types and subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry.

Results: GATA3 positivity was found in 69 different tumor types including 23 types (18%) with at least one strongly positive tumor. Highest positivity rates occurred in noninvasive papillary urothelial carcinoma (92-99%), lobular carcinoma (98%), carcinoma of no special type of the breast (92%), basal cell carcinoma of the skin (97%), invasive urothelial carcinoma (73%), T-cell lymphoma (23%), adenocarcinoma of the salivary gland (16%), squamous cell carcinoma of the skin (16%), and colorectal neuroendocrine carcinoma (12%). In breast cancer, low GATA3 staining was linked to high pT stage (p = 0.03), high BRE grade (p < 0.0001), HER2 overexpression (p = 0.0085), estrogen and progesterone receptor negativity (p < 0.0001 each), and reduced survival (p = 0.03).

Conclusion: Our data demonstrate that GATA3 positivity can occur in various tumor entities. Low levels of GATA3 reflect cancer progression and poor patient prognosis in breast cancer.

查看原文本刊更多论文

人类肿瘤中 GATA3 的表达：对 16,557 例肿瘤的组织芯片研究

引言GATA3 是一种参与上皮细胞分化的转录因子。GATA3 免疫染色被用作乳腺癌和尿道癌的诊断标志物，但也可能出现在其他肿瘤中：为了评估正常组织和肿瘤组织中的 GATA3，我们用免疫组化方法分析了一个组织芯片，其中包含来自 131 种不同肿瘤类型和亚型的 16,557 个样本，以及来自 76 种不同正常组织类型的 608 个样本：结果：在 69 种不同类型的肿瘤中发现了 GATA3 阳性，其中 23 种类型（18%）至少有一种肿瘤呈强阳性。阳性率最高的是非浸润性乳头状尿路上皮癌（92%-99%）、小叶癌（98%）、乳腺无特殊类型癌（92%）、皮肤基底细胞癌（97%）、浸润性尿路上皮癌（73%）、T 细胞淋巴瘤（23%）、唾液腺腺癌（16%）、皮肤鳞状细胞癌（16%）和结直肠神经内分泌癌（12%）。在乳腺癌中，低GATA3染色与pT分期高（p = 0.03）、BRE分级高（p < 0.0001）、HER2过表达（p = 0.0085）、雌激素和孕激素受体阴性（p < 0.0001）和生存率降低（p = 0.03）有关：我们的数据表明，GATA3 阳性可出现在各种肿瘤实体中。结论：我们的数据表明，GATA3 阳性可出现在不同的肿瘤实体中，低水平的 GATA3 反映了癌症的进展和乳腺癌患者的不良预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pathobiology 医学-病理学

CiteScore

8.50

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： ''Pathobiology'' offers a valuable platform for the publication of high-quality original research into the mechanisms underlying human disease. Aiming to serve as a bridge between basic biomedical research and clinical medicine, the journal welcomes articles from scientific areas such as pathology, oncology, anatomy, virology, internal medicine, surgery, cell and molecular biology, and immunology. Published bimonthly, ''Pathobiology'' features original research papers and reviews on translational research. The journal offers the possibility to publish proceedings of meetings dedicated to one particular topic.